Executive Vice President, Research and Development · Protalix BioTherapeutics, Inc. (PLX)

Yoseph Shaaltiel

A named executive officer of Protalix BioTherapeutics in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$468,321

Salary $290,926

FY2018: $433,442

2nd of 7 named executive officers at Protalix BioTherapeutics by FY2019 total.

7 named officers on file for Protalix BioTherapeutics, FY2019

Yoseph Shaaltiel’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • PLX’s disclosed peer group of 7 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Protalix BioTherapeutics’s whole pay program stands against its peers

  • Protalix BioTherapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on PLX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 15, 2020 (DEF 14A).

Free

Get Yoseph Shaaltiel’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Yoseph Shaaltiel compensation by year

Protalix BioTherapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Protalix BioTherapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$270,248$288,326$288,719$290,926
Bonus$0$62,176——
Stock awards$18,211———
Option awards$103,279$41,454$60,575$94,012
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$73,325$80,786$84,148$83,383
Total$465,063$472,742$433,442$468,321

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Protalix BioTherapeutics, Inc. DEF 14A filed April 15, 2020, accession 0001104659-20-046926, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Protalix BioTherapeutics, Inc. filed document, accession 0001104659-20-046926. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2020.

$465K
$473K
$433K
$468K
FY16
FY17
FY18
FY19
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option48,125—$5.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Protalix BioTherapeutics, Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Protalix BioTherapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Moshe ManorPresident and Chief Executive Officer$615,631
Yoseph Shaaltiel · this pageExecutive Vice President, Research and Development$468,321
Einat AlmonSenior Vice President, Product Development$422,181
Dror BashanPresident and Chief Executive Officer$391,599
Yaron NaosSenior Vice President, Operations$385,739
Yossi MaimonVice President, Chief Financial Officer$306,248
Eyal RubinSenior Vice President, Chief Financial Officer$154,206

The full Protalix BioTherapeutics compensation record

free company brief

This page is one person within Protalix BioTherapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Protalix BioTherapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Protalix BioTherapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Yoseph Shaaltiel's compensation dossier · One-time report. No refunds.